Number of patients (n)

Percentage (%)

Performance Status

1

28

33.33

2

46

54.76

3

10

11.90

Features

Dysuria

7

8.33

Pollakiuria

17

20.24

Bleeding

5

5.95

Bone pain

55

65.48

Initial metastatic site

Bone

65

77.38

Liver

4

4.76

Lung

13

15.48

Brain

2

2.38

PSA rate

<50

15

17.86

[50 - 100]

47

55.95

>100

22

26.19

Histology

only Adenocarcinoma

78

92.86

Adenocarcinoma + CNE

6

7.14

Gleason score

<7

17

20.24

7

29

34.52

>7

38

45.24

Previous therapeutics

LH-RH analogs + Anti-androgen (BAC)

31

36.90

LH-RH analogs (BAI)

42

50

Pulpectomy

11

13.01